Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes.

ABSTRACT:

Purpose

Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines.

Methods

This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25%. The women kept a daily hot flash diary during a

SUBMITTER: Kadakia KC 

PROVIDER: S-EPMC4973573 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature